MARTA MORAWSKA

Abstract Plasma cell myeloma (PCM) is the second most common type of haematological cancer. Lytic lesions and bone pain are among the most common symptoms of PCM. The study aimed to evaluated the diagnostic and prognostic value of markers of bone metabolism, i.e. activin A, Dkk-1, GDF-15, β-CTX and sclerostin in patients with PCM. The study involved 76 patients with PCM and 25 healthy volunteers. The concentration of above markers was determined by ELISA method.

CorrigendumVolume 94103904Open access Affiliations & Notes aWrocław Medical University, Wrocław, Poland bMedical University of Gdańsk, Gdańsk, Poland cMedical University of Lublin, Lublin, Poland dMedical University of Warsaw, Warsaw, Poland eInstitute of Hematology and Blood Transfusion, Warsaw, Poland fPoznań University of Medical Sciences, Poznań, Poland gMaria Sklodowska-Curie National Research Institute of Oncology, Poland Article Info Publication History: Published April 9, 2026 DOI:...

Keywords Waldenström macroglobulinaemia Obinutuzumab monotherapy Immunotherapy CD20 antibody Lymphoplasmacytic lymphoma Evidence before this study Despite advances in the treatment of Waldenström macroglobulinaemia, the disease remains incurable. For patients who relapse, the prognosis is not favourable. Rituximab based fixed duration therapy is a cornerstone of treatment for Waldenström macroglobulinemia.